Systemic methotrexate for the treatment of psoriasis

References

• Boehncke WH, Katsambas A, Ortonne JP, Puig L. EADV preceptorship: advances in dermatology. J Eur Acad Dermatol Venereol 2010;24(Suppl 5):2-24
   PubMed Web of Science ®Google Scholar
• Parisi R, Symmons DP, Griffiths CE, et al. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol 2013;133:377-85
   PubMed Web of Science ®Google Scholar
• Ros S, Puig L, Carrascosa JM. Cumulative life course impairment: the imprint of psoriasis on the patient’s life. Actas Dermosifiliogr 2014;105:128-34
   PubMedGoogle Scholar
• Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med 2009;361:496-509
   PubMed Web of Science ®Google Scholar
• Montaudie H, Sbidian E, Paul C, et al. Methotrexate in psoriasis: a systematic review of treatment modalities, incidence, risk factors and monitoring of liver toxicity. J Eur Acad Dermatol Venereol 2011;25(Suppl 2):12-18
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Langley RG, Strober BE, et al. A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis. Br J Dermatol 2012;167:649-57
   PubMed Web of Science ®Google Scholar
• Smolen JS, Emery P, Fleischmann R, et al. Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. Lancet 2014;383:321-32
   PubMed Web of Science ®Google Scholar
• Krieckaert CL, Bartelds GM, Lems WF, Wolbink GJ. The effect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies: a review. Arthritis Res Ther 2010;12:217
   PubMed Web of Science ®Google Scholar
• Puig Sanz L, Saez E, Lozano MJ, et al. [Reactions to infliximab infusions in dermatologic patients: consensus statement and treatment protocol. Working group of the grupo espanol de psoriasis de la academia espanola de dermatologia y venereologia]. Actas Dermosifiliogr 2009;100:103-12
   PubMedGoogle Scholar
• Hsu L, Snodgrass BT, Armstrong AW. Antidrug antibodies in psoriasis: a systematic review. Br J Dermatol 2014;170:261-73
   PubMed Web of Science ®Google Scholar
• Maneiro JR, Salgado E, Gomez-Reino JJ. Immunogenicity of monoclonal antibodies against tumor necrosis factor used in chronic immune-mediated Inflammatory conditions: systematic review and meta-analysis. JAMA Intern Med 2013;173:1416-28
   PubMed Web of Science ®Google Scholar
• Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552-63
   PubMed Web of Science ®Google Scholar
• Vermeire S, Noman M, Van Assche G, et al. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn’s disease. Gut 2007;56:1226-31
   PubMed Web of Science ®Google Scholar
• Calasan MB, Wulffraat NM. Methotrexate in juvenile idiopathic arthritis: towards tailor-made treatment. Expert Rev Clin Immunol 2014;10:843-54
   PubMed Web of Science ®Google Scholar
• Gossec L, Smolen JS, Gaujoux-Viala C, et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis 2012;71:4-12
   PubMed Web of Science ®Google Scholar
• Gottlieb A, Korman NJ, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol 2008;58:851-64
   PubMed Web of Science ®Google Scholar
• van Bezooijen JS, Prens EP, Pradeepti MS, et al. Combining biologics with methotrexate in psoriasis: a systematic review. Br J Dermatol 2014. [Epub ahead of print]
   Web of Science ®Google Scholar
• Menter A, Papp KA, Tan H, et al. Efficacy of tofacitinib, an oral janus kinase inhibitor, on clinical signs of moderate-to-severe plaque psoriasis in different body regions. J Drugs Dermatol 2014;13:252-6
   PubMed Web of Science ®Google Scholar
• Mesa RA. Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis. IDrugs 2010;13:394-403
   PubMed Web of Science ®Google Scholar
• Kwatra SG, Dabade TS, Gustafson CJ, Feldman SR. JAK inhibitors in psoriasis: a promising new treatment modality. J Drugs Dermatol 2012;11:913-18
   PubMed Web of Science ®Google Scholar
• Shi JG, Chen X, Lee F, et al. The pharmacokinetics, pharmacodynamics and safety of baricitinib, an oral JAK 1/2 inhibitor, in healthy volunteers. J Clin Pharmacol 2014;54(12):1354-61
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Matheson RT, Menter A, et al. Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study. J Drugs Dermatol 2013;12:888-97
   PubMed Web of Science ®Google Scholar
• Kofoed K, Skov L, Zachariae C. New drugs and treatment targets in psoriasis. Acta Derm Venereol 2015;95(2):133-9
   PubMed Web of Science ®Google Scholar
• Pathirana D, Ormerod AD, Saiag P, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009;23(Suppl 2):1-70
   PubMed Web of Science ®Google Scholar
• Samarasekera E, Sawyer L, Parnham J, et al. Assessment and management of psoriasis: summary of NICE guidance. BMJ 2012;345:e6712
   PubMed Web of Science ®Google Scholar
• Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol 2009;61:451-85
   PubMed Web of Science ®Google Scholar
• Gumusel M, Ozdemir M, Mevlitoglu I, Bodur S. Evaluation of the efficacy of methotrexate and cyclosporine therapies on psoriatic nails: a one-blind, randomized study. J Eur Acad Dermatol Venereol 2011;25:1080-4
   PubMed Web of Science ®Google Scholar
• Sandhu K, Kaur I, Kumar B, Saraswat A. Efficacy and safety of cyclosporine versus methotrexate in severe psoriasis: a study from north India. J Dermatol 2003;30:458-63
   PubMed Web of Science ®Google Scholar
• Kumar B, Saraswat A, Kaur I. Short-term methotrexate therapy in psoriasis: a study of 197 patients. Int J Dermatol 2002;41:444-8
   PubMed Web of Science ®Google Scholar
• Maybury CM, Jabbar-Lopez ZK, Wong T, et al. Methotrexate and liver fibrosis in people with psoriasis: a systematic review of observational studies. Br J Dermatol 2014;171:17-29
   PubMed Web of Science ®Google Scholar
• Chladek J, Simkova M, Vaneckova J, et al. The effect of folic acid supplementation on the pharmacokinetics and pharmacodynamics of oral methotrexate during the remission-induction period of treatment for moderate-to-severe plaque psoriasis. Eur J Clin Pharmacol 2008;64:347-55
   PubMed Web of Science ®Google Scholar
• Chladek J, Grim J, Martinkova J, et al. Pharmacokinetics and pharmacodynamics of low-dose methotrexate in the treatment of psoriasis. Br J Clin Pharmacol 2002;54:147-56
   PubMed Web of Science ®Google Scholar
• Hayashi H, Tazoe Y, Tsuboi S, et al. A single nucleotide polymorphism of reduced folate carrier 1 predicts methotrexate efficacy in Japanese patients with rheumatoid arthritis. Drug Metab Pharmacokinet 2013;28:164-8
   PubMed Web of Science ®Google Scholar
• Puig L. Methotrexate: new therapeutic approaches. Actas Dermosifiliogr 2014;105:583-9
   PubMedGoogle Scholar
• Tian H, Cronstein BN. Understanding the mechanisms of action of methotrexate: implications for the treatment of rheumatoid arthritis. Bull NYU Hosp Jt Dis 2007;65:168-73
   PubMedGoogle Scholar
• Hoekstra M, Haagsma C, Neef C, et al. Splitting high-dose oral methotrexate improves bioavailability: a pharmacokinetic study in patients with rheumatoid arthritis. J Rheumatol 2006;33:481-5
   PubMed Web of Science ®Google Scholar
• Ando Y, Shimada H, Matsumoto N, et al. Role of methotrexate polyglutamation and reduced folate carrier 1 (RFC1) gene polymorphisms in clinical assessment indexes. Drug Metab Pharmacokinet 2013;28:442-5
   PubMed Web of Science ®Google Scholar
• Baggott JE, Morgan SL. Methotrexate catabolism to 7-hydroxymethotrexate in rheumatoid arthritis alters drug efficacy and retention and is reduced by folic acid supplementation. Arthritis Rheum 2009;60:2257-61
   PubMed Web of Science ®Google Scholar
• Yélamos O, Català A, Vilarrasa E, et al. Acute severe methotrexate toxicity in patients with psoriasis: a case series and discussion. Dermatology 2014;229(4):306-9
   PubMed Web of Science ®Google Scholar
• Woolf RT, West SL, Arenas-Hernandez M, et al. Methotrexate polyglutamates as a marker of patient compliance and clinical response in psoriasis: a single-centre prospective study. Br J Dermatol 2012;167:165-73
   PubMed Web of Science ®Google Scholar
• Hider SL, Bruce IN, Thomson W. The pharmacogenetics of methotrexate. Rheumatology (Oxford) 2007;46:1520-4
   PubMed Web of Science ®Google Scholar
• Warren RB, Smith RL, Campalani E, et al. Genetic variation in efflux transporters influences outcome to methotrexate therapy in patients with psoriasis. J Invest Dermatol 2008;128:1925-9
   PubMed Web of Science ®Google Scholar
• Bookstaver PB, Norris L, Rudisill C, et al. Multiple toxic effects of low-dose methotrexate in a patient treated for psoriasis. Am J Health Syst Pharm 2008;65:2117-21
   PubMed Web of Science ®Google Scholar
• Chan ES, Cronstein BN. Methotrexate–how does it really work? Nat Rev Rheumatol 2010;6:175-8
   PubMed Web of Science ®Google Scholar
• Prey S, Paul C. Effect of folic or folinic acid supplementation on methotrexate-associated safety and efficacy in inflammatory disease: a systematic review. Br J Dermatol 2009;160:622-8
   PubMed Web of Science ®Google Scholar
• Paul C, Gallini A, Maza A, et al. Evidence-based recommendations on conventional systemic treatments in psoriasis: systematic review and expert opinion of a panel of dermatologists. J Eur Acad Dermatol Venereol 2011;25(Suppl 2):2-11
   PubMed Web of Science ®Google Scholar
• Salim A, Tan E, Ilchyshyn A, Berth-Jones J. Folic acid supplementation during treatment of psoriasis with methotrexate: a randomized, double-blind, placebo-controlled trial. Br J Dermatol 2006;154:1169-74
   PubMed Web of Science ®Google Scholar
• Wessels JA, Huizinga TW, Guchelaar HJ. Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis. Rheumatology (Oxford) 2008;47:249-55
   PubMed Web of Science ®Google Scholar
• Peng Z, Borea PA, Varani K, et al. Adenosine signaling contributes to ethanol-induced fatty liver in mice. J Clin Invest 2009;119:582-94
   PubMed Web of Science ®Google Scholar
• Peng Z, Fernandez P, Wilder T, et al. Ecto-5’-nucleotidase (CD73) -mediated extracellular adenosine production plays a critical role in hepatic fibrosis. FASEB J 2008;22:2263-72
   PubMed Web of Science ®Google Scholar
• Swanson DL, Barnes SA, Mengden Koon SJ, el-Azhary RA. Caffeine consumption and methotrexate dosing requirement in psoriasis and psoriatic arthritis. Int J Dermatol 2007;46:157-9
   PubMed Web of Science ®Google Scholar
• Stenberg D. Neuroanatomy and neurochemistry of sleep. Cell Mol Life Sci 2007;64:1187-204
   PubMed Web of Science ®Google Scholar
• Bernini JC, Fort DW, Griener JC, et al. Aminophylline for methotrexate-induced neurotoxicity. Lancet 1995;345:544-7
   PubMed Web of Science ®Google Scholar
• Lajevardi V, Hallaji Z, Daklan S, et al. The efficacy of methotrexate plus pioglitazone vs. methotrexate alone in the management of patients with plaque-type psoriasis: a single-blinded randomized controlled trial. Int J Dermatol 2015;54(1):95-101
   PubMed Web of Science ®Google Scholar
• Heydendael VM, Spuls PI, Opmeer BC, et al. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med 2003;349:658-65
   PubMed Web of Science ®Google Scholar
• Flytström I, Stenberg B, Svensson A, Bergbrant IM. Methotrexate vs. cyclosporine in psoriasis: effectiveness, quality of life and safety. A randomized controlled trial. Br J Dermatol 2008;158:116-21
   PubMed Web of Science ®Google Scholar
• Saurat JH, Stingl G, Dubertret L, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008;158:558-66
   PubMed Web of Science ®Google Scholar
• Barker J, Hoffmann M, Wozel G, et al. Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1). Br J Dermatol 2011;165:1109-17
   PubMed Web of Science ®Google Scholar
• Reich K, Langley RG, Papp KA, et al. A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis. N Engl J Med 2011;365:1586-96
   PubMed Web of Science ®Google Scholar
• Janagond AB, Kanwar AJ, Handa S. Efficacy and safety of systemic methotrexate vs. acitretin in psoriasis patients with significant palmoplantar involvement: a prospective, randomized study. J Eur Acad Dermatol Venereol 2013;27:e384-9
   PubMed Web of Science ®Google Scholar
• Lee EB, Fleischmann R, Hall S, et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med 2014;370:2377-86
   PubMed Web of Science ®Google Scholar
• Dogra S, Mahajan R. Systemic methotrexate therapy for psoriasis: past, present and future. Clin Exp Dermatol 2013;38:573-88
   PubMed Web of Science ®Google Scholar
• Carretero G, Puig L, Dehesa L, et al. Metotrexato: guía de uso en psoriasis. Actas Dermosifiliogr 2010;101:600-13
   PubMedGoogle Scholar
• Saurat JH, Langley RG, Reich K, et al. Relationship between methotrexate dosing and clinical response in patients with moderate to severe psoriasis: subanalysis of the CHAMPION study. Br J Dermatol 2011;165:399-406
   PubMed Web of Science ®Google Scholar
• Chiaravalloti AJ, Strober BE. The use of self-administered subcutaneous methotrexate for the treatment of psoriasis. J Drugs Dermatol 2014;13:929-31
   PubMed Web of Science ®Google Scholar
• Bulatovic M, Heijstek MW, Van Dijkhuizen EH, et al. Prediction of clinical non-response to methotrexate treatment in juvenile idiopathic arthritis. Ann Rheum Dis 2012;71:1484-9
   PubMed Web of Science ®Google Scholar
• Lucas J, Ntuen E, Pearce DJ, et al. Methotrexate: understanding the risk in psoriasis patients. J Dermatolog Treat 2009;20:311-13
   PubMed Web of Science ®Google Scholar
• Metotrexato por vía oral: reacciones adversas graves derivadas de la confusión en la dosis administrada. Agencia Española de Medicamentos y Productos Sanitarios. 2011. Available from: www.aemps.gob.es/informa/notasInformativas/medicamentosUsoHumano/seguridad/2011/NI-MUH_11-2011.htm [Last accessed 12 November 2014]
   Google Scholar
• Methotrexate Safety information. U.S. Food and Drug Administration. 2011. Available from: www.accessdata.fda.gov/drugsatfda_docs/label/2011/011719s117lbl.pdf [Last accessed 12 November 2014]
   Google Scholar
• Improving compliance with oral methotrexate guidelines. The National Patient Safety Agency, London, UK; 2007. Available from: www.nrls.npsa.nhs.uk/resources/?entryid45=59800 [Last accessed 12 November 2014]
   Google Scholar
• Potential signals of serious risks/new safety information identified by the adverse event reporting system (AERS) between April - June 2011. U.S. Food and Drug Administration. 2014. Available from: www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/ucm270938.htm [Last accessed 12 November 2014]
   Google Scholar
• Kozma C, Ramasethu J. Methotrexate and misoprostol teratogenicity: further expansion of the clinical manifestations. Am J Med Genet A 2011;155A:1723-8
   PubMed Web of Science ®Google Scholar
• Weber-Schoendorfer C, Hoeltzenbein M, Wacker E, et al. No evidence for an increased risk of adverse pregnancy outcome after paternal low-dose methotrexate: an observational cohort study. Rheumatology (Oxford) 2014;53:757-63
   PubMed Web of Science ®Google Scholar
• Maroñas-Jiménez L, Castellanos-González M, Sanz Bueno J, Vanaclocha Sebastián F. Erosiones y úlceras acrales: manifestación precoz de toxicidad aguda grave por metrotexato. Actas Dermosifiliogr 2014;105:322-3
   PubMedGoogle Scholar
• Fridlington JL, Tripple JW, Reichenberg JS, et al. Acute methotrexate toxicity seen as plaque psoriasis ulceration and necrosis: a diagnostic clue. Dermatol Online J 2011;17:2
   PubMedGoogle Scholar
• Ficha tecnica del Metotrexato. Agencia Española de Medicamentos y Productos Sanitarios. 2014. Available from: http://www.aemps.gob.es/cima/pdfs/es/ft/40698/FT_40698.pdf [Last accessed 12 March 2015]
   Google Scholar
• Renard D, Westhovens R, Vandenbussche E, Vandenberghe R. Reversible posterior leucoencephalopathy during oral treatment with methotrexate. J Neurol 2004;251:226-8
   PubMed Web of Science ®Google Scholar
• Mohyuddin T, Elyan M, Kushner I. Pericarditis: a rare complication of methotrexate therapy. Clin Rheumatol 2007;26:2157-8
   PubMed Web of Science ®Google Scholar
• Forbat LN, Hancock BW, Gershlick AH. Methotrexate-induced pericarditis and pericardial effusion; first reported case. Postgrad Med J 1995;71:244-5
   PubMed Web of Science ®Google Scholar
• Savoia F, Gaddoni G, Casadio C, et al. A case of aseptic pleuropericarditis in a patient with chronic plaque psoriasis under methotrexate therapy. Dermatol Online J 2010;16:13
   PubMedGoogle Scholar
• Moreira DM, da Silva RL, Vieira JL, et al. Role of vascular inflammation in coronary artery disease: potential of anti-inflammatory drugs in the prevention of atherothrombosis: inflammation and anti-inflammatory drugs in coronary artery disease. Am J Cardiovasc Drugs 2015;15(1):1-11
   PubMed Web of Science ®Google Scholar
• Westlake SL, Colebatch AN, Baird J, et al. The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford) 2010;49:295-307
   PubMed Web of Science ®Google Scholar
• Naranjo A, Sokka T, Descalzo MA, et al. Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthritis Res Ther 2008;10:R30
   PubMed Web of Science ®Google Scholar
• Moreira DM, Lueneberg ME, da Silva RL, et al. Rationale and design of the TETHYS trial: the effects of methotrexate therapy on myocardial infarction with ST-segment elevation. Cardiology 2013;126:167-70
   PubMed Web of Science ®Google Scholar
• Micha R, Imamura F, Wyler von Ballmoos M, et al. Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol 2011;108:1362-70
   PubMed Web of Science ®Google Scholar
• Barker J, Horn EJ, Lebwohl M, et al. Assessment and management of methotrexate hepatotoxicity in psoriasis patients: report from a consensus conference to evaluate current practice and identify key questions toward optimizing methotrexate use in the clinic. J Eur Acad Dermatol Venereol 2011;25:758-64
   PubMed Web of Science ®Google Scholar
• Zachariae H. Have methotrexate-induced liver fibrosis and cirrhosis become rare? A matter for reappraisal of routine liver biopsies. Dermatology 2005;211:307-8
   PubMed Web of Science ®Google Scholar
• Gyulai R, Bagot M, Griffiths CE, et al. Current practice of methotrexate use for psoriasis: results of a worldwide survey among dermatologists. J Eur Acad Dermatol Venereol 2015;29(2):224-31
   Web of Science ®Google Scholar
• Kalb RE, Strober B, Weinstein G, Lebwohl M. Methotrexate and psoriasis: 2009 national psoriasis foundation consensus conference. J Am Acad Dermatol 2009;60:824-37
   PubMed Web of Science ®Google Scholar
• Gisondi P, Fantuzzi F, Malerba M, Girolomoni G. Folic acid in general medicine and dermatology. J Dermatolog Treat 2007;18:138-46
   PubMed Web of Science ®Google Scholar
• Maybury CM, Samarasekera E, Douiri A, et al. Diagnostic accuracy of noninvasive markers of liver fibrosis in patients with psoriasis taking methotrexate: a systematic review and meta-analysis. Br J Dermatol 2014;170:1237-47
   PubMed Web of Science ®Google Scholar
• Lynch M, Higgins E, McCormick PA, et al. The use of transient elastography and FibroTest for monitoring hepatotoxicity in patients receiving methotrexate for psoriasis. JAMA Dermatol 2014;150:856-62
   PubMed Web of Science ®Google Scholar
• Zachariae H, Heickendorff L, Sogaard H. The value of amino-terminal propeptide of type III procollagen in routine screening for methotrexate-induced liver fibrosis: a 10-year follow-up. Br J Dermatol 2001;144:100-3
   PubMed Web of Science ®Google Scholar
• Chalmers RJ, Kirby B, Smith A, et al. Replacement of routine liver biopsy by procollagen III aminopeptide for monitoring patients with psoriasis receiving long-term methotrexate: a multicentre audit and health economic analysis. Br J Dermatol 2005;152:444-50
   PubMed Web of Science ®Google Scholar
• Lindsay K, Fraser AD, Layton A, et al. Liver fibrosis in patients with psoriasis and psoriatic arthritis on long-term, high cumulative dose methotrexate therapy. Rheumatology (Oxford) 2009;48:569-72
   PubMed Web of Science ®Google Scholar
• Collin B, Vani A, Ogboli M, Moss C. Methotrexate treatment in 13 children with severe plaque psoriasis. Clin Exp Dermatol 2009;34:295-8
   PubMed Web of Science ®Google Scholar